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Background: In type 1 diabetic patients, who have lost their ability to produce insulin,
transplantation of pancreatic islet cells can normalize metabolic control in a manner
that is not achievable with exogenous insulin. To be successful, this procedure has to
address the problems caused by the immune and autoimmune responses to the graft.
Islet encapsulation using various techniques and materials has been and is being
extensively explored as a possible approach. Within this framework, it is of considerable
interest to characterize the effect encapsulation has on the insulin response of
pancreatic islets.
Methods: To improve our ability to quantitatively describe the glucose-stimulated
insulin release (GSIR) of pancreatic islets in general and of micro-encapsulated islets
in particular, we performed dynamic perifusion experiments with frequent sampling.
We used unencapsulated and microencapsulated murine islets in parallel and fitted the
results with a complex local concentration-based finite element method (FEM)
computational model.
Results: The high-resolution dynamic perifusion experiments allowed good
characterization of the first-phase and second-phase insulin secretion, and we observed
a slightly delayed and blunted first-phase insulin response for microencapsulated islets
when compared to free islets. Insulin secretion profiles of both free and encapsulated
islets could be fitted well by a COMSOL Multiphysics model that couples hormone
secretion and nutrient consumption kinetics with diffusive and convective transport.
This model, which was further validated and calibrated here, can be used for arbitrary
geometries and glucose stimulation sequences and is well suited for the quantitative
characterization of the insulin response of cultured, perifused, transplanted, or
encapsulated islets.
Conclusions: The present high-resolution GSIR experiments allowed for direct
characterization of the effect microencapsulation has on the time-profile of insulin
secretion. The multiphysics model, further validated here with the help of these
experimental results, can be used to increase our understanding of the challenges
that have to be faced in the design of bioartificial pancreas-type devices and to
advance their further optimization.
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waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
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To maintain glucose homeostasis, patients with type 1 diabetes mellitus (T1D) require
continuous glucose monitoring and exogenous insulin treatment due to the autoimmune
destruction of their insulin-producing β-cells. In healthy humans, these β-cells, which are
located in pancreatic islets, provide a finely-tuned glucose-insulin control system that
maintains blood glucose levels within a relatively narrow range (typically 4–5 mM and
usually within 3.5–7.0 mM, i.e., 60–125 mg/dL in fasting subjects) [1,2]. For T1D patients,
exogenous insulin delivered via injections or pumps can provide a solution; however,
because these therapies cannot fully mimic the inherently complex function of the
endocrine pancreas, they are ultimately inadequate, leading to chronic and degenerative
complications [3].
Transplantation of pancreatic islet cells can normalize metabolic control in a manner
that is not achievable with exogenous insulin. This approach is being explored as an ex-
perimental therapy in a select cohort of patients [4,5]. One of the primary challenges
impacting islet graft survival in these patients is the compounded immune and autoimmune
response to the graft, necessitating life-long immunosuppression that comes with a
host of adverse side effects. The encapsulation of islets using various techniques and
materials has been extensively explored as a possible approach to circumvent life-long
immunosuppression [6-10]. One of the most commonly used biomaterials for such
purposes is alginate. It is an algae-derived or seaweed-derived anionic polysaccharide
comprised of unbranched polymers of 1,4-linked β-D-mannuronic and α-L-guluronic
acid residues, which form a gel in the presence of multivalent cations such as Ca2+ or
Ba2+. Such approaches have their own challenges: for example, failed clinical and pre-
clinical attempts [11,12] make it clear that minimizing the volume of encapsulating
material and the corresponding diffusional limitations are crucial for graft success.
Within this context, quantitative models that assist in predicting and understanding
the islet microenvironment needed for proper functioning are of considerable relevance
to the optimization of future designs. Furthermore, models that can describe the glucose–
insulin regulatory system are of obvious general interest. Several have been developed and
some are also used in clinical practice, for example, to estimate glucose effectiveness and
insulin sensitivity from intravenous glucose tolerance tests (IVGTT) [13]. While some
models of insulin release from encapsulated islets have been published [14-20], none of
them allow the coupling of both convective and diffusive transport with reactive rates for
arbitrary geometries. Most of these models allowed transport by diffusion only, and just a
couple incorporated convective transport (i.e., fluid dynamics to model flow) [15,18], and
even these were restricted by having to assume cylindrical symmetry. We have recently
developed a finite element method (FEM)–based glucose-insulin model for avascular is-
lets that uses an unrestricted approach to couple local (i.e., cellular level) hormone release
and nutrient consumption rates with mass transport by convection and diffusion. It can
be used for arbitrary geometries including those with flowing fluid phases to calculate in-
sulin output in response to arbitrary incoming glucose profiles [21]. Furthermore, the
model can account for both first-phase and second-phase insulin responses, as well as
for the glucose-dependence and oxygen-dependence of insulin release. In avascular is-
lets, hypoxia due to oxygen diffusion limitations is likely a major limiting factor
[22-27]. Therefore, it is important to incorporate this aspect into the glucose–insulin
response model. As our model is particularly well-suited to describe the behavior of
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experiments, we performed parallel perifusion experiments with rodent islets and fre-
quent sampling (every minute) to quantify the effect that microencapsulation has on
the time-profile of insulin secretion and used the results to further calibrate and val-
idate our FEM-based computational model.Methods
Islet isolation and encapsulation
All animal studies were reviewed and approved by the University of Miami Institutional
Animal Care and Use Committee. All procedures were conducted according to the
guidelines of the Committee on Care and Use of Laboratory Animals, Institute of
Laboratory Animal Resources (National Research Council, Washington DC). Animals
were housed in microisolated cages in Virus Antibody Free rooms with free access to
autoclaved food and water at the Department of Veterinary Resources of the University of
Miami. The Preclinical Cell Processing and Translational Models Core at the Diabetes
Research Institute performed the rodent islet isolations. Islets were obtained from
donor mice (BALB/C, Jackson Lab, Bar Harbor, ME) via mechanically enhanced en-
zymatic digestion followed by density gradient purification, as previously described
[28,29]. Islet purity was assessed by dithizone (Sigma-Aldrich) staining, and islets
were counted and scored using a standard algorithm for the calculation of 150 μm
diameter islet equivalent (IEQ) number [30,31]. Islets were cultured in completed
CMRL 1066-based medium (Mediatech), which is CMRL 1066 supplemented with
10% fetal bovine serum (FBS; Sigma), 20 × 10−3 M Hepes Buffer, 1% penicillin-
streptomycin (Sigma-Aldrich), and 1% L-glutamine (Sigma-Aldrich). Islets were cultured
for 48 h prior to encapsulation.
For encapsulation, standard Ba-Alg microbeads were fabricated using a modification
of the protocol originally developed by Lim and Sun [32]. As previously published, 1.6%
(w/v) alginate (UP-MVG, Mw= 300 kDa, Mw/Mn= 1.87, DPn of 28, Batch # FP-504-03,
Pronova Novamatrix, FMC) dissolved in phosphate-buffered solution (PBS, Mediatech)
was homogeneously mixed with pelleted mouse islets prior to extrusion through a
microbead generator (Biorep Technologies, Inc., Miami, FL) into a crosslinking bath of
1.5% (w/v) barium chloride, supplemented with 10 mM 3-(N-morpholino)propanesulfonic
acid (MOPS), 140 mM D-Mannitol, and 0.025% Tween-20. After crosslinking (10 min),
microbeads were washed with PBS and cultured for 48 h prior to study. Resulting
microbeads were an average size of 800 μm.Islet perifusion
The perifusion experiments (dynamic glucose-stimulated insulin release, GSIR) were
performed using a custom built apparatus that allows parallel perifusion in up to eight
channels (Biorep). Fifty IEQ of unencapsulated or encapsulated islets were handpicked
and loaded in Perspex microcolumns, between two layers of acrylamide-based microbead
slurry (Bio-Gel P-4, Bio-Rad Laboratories, Hercules, CA). Perifusing buffer containing
125 mM NaCl, 5.9 mM KCl, 1.28 mM CaCl2, 1.2 mM MgCl2, 25 mM HEPES, 0.1%
bovine serum albumin, and 3 mM glucose at 37°C with selected glucose (low = 3 mM;
high = 11 mM) or KCl (25 mM) concentrations was circulated through the columns
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tion for stabilization, islets were stimulated with the following sequence: 5 min of low
glucose, 20 min of high glucose, 15 min of low glucose, 5 min of KCl, and 10 min of
low glucose. Serial samples (100 μL) were collected every minute from the outflow
tubing of the columns in an automatic fraction collector designed for a multi-well
plate format. The sample container harboring the islets and the perifusion solutions
were kept at 37°C in a built-in temperature controlled chamber. The perifusate in the
collecting plate was kept at <4°C to preserve the integrity of the analytes. Insulin con-
centrations were determined with a commercially available ELISA kit (Mercodia Inc.,
Winston Salem, NC). To account for possible differences in viability/purity across ex-
periments as well as in IEQ numbers among islets in different channels, values were
rescaled by up to 30% taking into account the KCl-induced release as a normalization
factor for each condition. Data used here are averages of duplicate samples for both
free and encapsulated islets perifused in parallel from three independent experiments.Computational methods
For computational modeling, our previously developed local concentration-based insu-
lin secretion model has been used. A conceptual schematic of the model is shown in
Figure 1; a detailed description of its implementation and parameterization can be
found in [21] (see also Additional file 1: Appendix 1). Here, only a brief summary is in-
cluded to permit interpretation and understanding of the results. A total of four con-
centrations were used for (convective and diffusive) mass transport modeling, with
their corresponding equations (application modes): glucose, oxygen, and ‘local’ and
released insulin (cgluc, coxy, cinsL, cins). Diffusion was assumed to be governed by the













Figure 1 Basic concept of the present model of insulin release in β-cells. Response is determined by
the local glucose concentration, cgluc, and its rate of change, ∂cgluc/∂t, but it is also influenced by the local
oxygen concentration, coxy.
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∂t
þ ∇ ⋅ −D∇cð Þ ¼ R−u⋅∇ c ð1Þ
where, c denotes the concentration [mol⋅m−3] and D the diffusion coefficient [m2⋅s−1]
of the species of interest, R the reaction rate [mol⋅m−3⋅s−1], u the velocity field [m⋅s−1],
and ∇ the standard del (nabla) operator (∇≡i ∂∂xþ j ∂∂yþ k ∂∂z). Diffusion coefficients (D)
used were the same as in the original model [21]; they were selected as consensus esti-
mates of values available from the literature. Values in the present implementation for
water, tissue (islet), and alginate (capsule) are as follows (all in m2⋅s−1) oxygen: 3.0 × 10−9,
2.0 × 10−9, 2.5 × 10−9; glucose: 0.9 × 10−9, 0.3 × 10−9, 0.6 × 10−9; and insulin: 0.15 × 10−9,
0.05 × 10−9, 0.1 × 10−9.
As an important part of the model, all consumption and release rates were assumed
to follow Hill–type dependence (generalized Michaelis-Menten kinetics) on the local
concentrations as this provides a convenient and easily parameterizable mathematical
function:




Parameters here were Rmax, the maximum reaction rate [mol⋅m
−3⋅s−1], CHf, the con-centration corresponding to half-maximal response [mol⋅m−3], and n, the Hill slope
characterizing the shape of the response. The parameter values used for the different
release and consumption functions (i.e., insulin, glucose, oxygen; e.g., CHf,gluc, CHf,oxy, etc.)
were different [21]; their values used in the model are summarized in Table 1.
For avascular islets, oxygen availability is a main limiting factor because the solubility
of oxygen in culture media or in tissue is much lower than that of glucose; hence, avail-
able oxygen concentrations are usually much more limited [21,26]. To account for the
increased metabolic demand of insulin release and production at higher glucose con-
centrations, the model also included a dependence of the oxygen consumption (Roxy) onTable 1 Summary of Hill function parameters used in the present model (Figure 1;
detailed equations in [21])
Rate Var. CHf n Rmax Property and comments
Roxy coxy 1 μM 1 −0.034 mol/m3/s Oxygen consumption, base. Cut to 0 below
critical value, coxy < Ccr,oxy.
Roxy cgluc 7 mM 2.5 N/A Oxygen consumption, φo,g metabolic part.
Due to increasing metabolic demand.
Parallels second-phase insulin secretion rate.
Rgluc cgluc 10 μM 1 −0.028 mol/m3/s Glucose consumption. Contrary to oxygen,
has no significant influence on model results.
Rins,ph2 cgluc 7 mM 2.5 3 × 10
−5 mol/m3/s Insulin secretion rate, second-phase. Total
secretion rate is modulated by local oxygen
availability (last row).
Rins,ph1 ∂cgluc/∂t 0.03 mM/s 2 21 × 10
−5 mol/m3/s Insulin secretion rate, first-phase. Modulated
to have maximum sensibility around
cgluc = 5 mM and be limited at very large
or low cgluc.
Rins, φo,g coxy 3 μM 3 N/A Insulin secretion rate, φo,g oxygen dependence.
Limits insulin secretion if coxy becomes
critically low.
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details). The core of the model was the functional form describing the glucose-dependence
of the insulin secretion rate, Rins. For this purpose, a combination of two sigmoid Hill func-
tions was used. One describes the glucose-insulin dynamics of the second-phase response
as a function of the local glucose concentration, cgluc, with the help of parameters shown in
the Rins,ph2 row of Table 1. The other describes the first-phase response as a function of the
(local) change in glucose concentration, i.e., glucose time-gradient (ct = ∂cgluc/∂t) with the
help of parameters shown in the Rins,ph1 row of Table 1. This was non-zero only when the
glucose concentration increased, i.e., only when ct > 0. We found that for a correct time-
scale of insulin release, an additional ‘local’ insulin compartment had to be added (Figure 1)
so that insulin was assumed to be first secreted into this compartment and then released
from here following a first order kinetics, dcinsL/dt = Rins − kinsL(cinsL − cins); for details, see
[21]. The original model, which was calibrated for human islets, used a corresponding rate
constant of kinsL = 0.003 s
−1. Here, to fit the data obtained with murine islets, this was in-
creased to 0.006 s−1 to have a slightly faster release; this was the only parameter modified
compared to the original model.
Finally, to incorporate media flow, these convection and diffusion models were
coupled to a fluid dynamics model. For this purpose, the incompressible Navier–Stokes
model for Newtonian flow (constant viscosity) was used to calculate the velocity field u






uþ ρ u⋅∇ð Þuþ ∇p ¼ F
∇ ⋅u ¼ 0
ð3Þ
The first equation is the momentum balance; the second is the equation of continuity
for incompressible fluids. Standard notation was used with ρ denoting density [kg⋅m−3],
η viscosity [kg⋅m−1⋅s−1 = Pa⋅s], p pressure [Pa, N⋅m−2, kg⋅m−1 ⋅s−2], and F volume force
[N⋅m−3, kg⋅m−2⋅s−2]. The flowing media was assumed to be an essentially aqueous
media at physiological temperature (37°C). Incoming media was assumed to be in
equilibrium with atmospheric oxygen and, thus, to have an oxygen concentration of
coxy,in = 0.200 mol⋅m
−3 (mM) corresponding to pO2 ≈ 140 mmHg. For physiologically
relevant conditions, lower values have to be used as tissue oxygen concentrations are
likely to be around only coxy,tis = 0.060 mol⋅m
−3 (mM) corresponding to pO2 ≈ 40 mmHg.
The model was implemented in COMSOL Multiphysics 4.4 (COMSOL Inc., Burlington,
MA) and solved as a time-dependent (transient) problem, allowing intermediate time-
steps for the solver, as described previously. Mesh and boundary conditions used were
also as described before [21] (see also Additional file 1: Appendix 1, Additional files for
further details). Similar to our previous models of human islet perifusions [21,34], here,
we also used two spherical islets of 100 and 150 μm diameter placed in a 2D cross-section
of a cylindrical tube with fluid flowing from left to right. Islets were considered homoge-
neous inside; individual cells (e.g., α- or β-cells) were not considered separately. Islet sizes
were selected based on our analysis of the size distribution of isolated islets [31].
This confirmed that the expected value of islet diameter is 95 μm, whereas the ex-
pected value of islet volume is 1.2 × 106 μm3, corresponding to the volume of an islet
with d = 133 μm [31].
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To accurately quantify the effect that microencapsulation has on the time-profile of in-
sulin secretion from isolated islets, we first performed high-resolution parallel perifu-
sion experiments with unencapsulated and alginate-encapsulated murine islets. Then,
we used the results to validate and further calibrate our FEM-based glucose-insulin
computational model. Perifusion was performed with four channels in parallel and using
a low (3 mM), high (11 mM), low (3 mM) glucose step with frequent sample collection
(every minute); the insulin response obtained is shown in Figure 2. To allow a clear delin-
eation of the first-phase response, the high glucose step (G11) was maintained for 20 min,
which is longer than in our previously used standard protocols [34–36]. Unencapsulated
islets demonstrated a well-defined first-phase peak, followed by a second-phase plateau,
with possibly a slightly rising tendency (Figure 2). This was expected, given normal func-
tioning islets release insulin in a biphasic manner in response to a stepwise increase of
glucose (e.g., a relatively quick transient spike of 5–10 min /first phase/ followed by a
sustained second phase that is slower and somewhat delayed [37–40]). Responses
from the encapsulated islets were similar, but slightly delayed and blunted. This was
again expected, due to the impact of the encapsulating hydrogel and agrees with published
reports [32,41,42].
Another important goal of the present work was to verify if these data can be fitted
by our recently developed complex FEM-based computational model [21]. This local
concentration-based model predicted a similar behavior for hydrogel-encapsulated is-
lets. Figure 3 shows the theoretical predicted values for a setup mimicking the present
experimental conditions. Two perifused islets that are in the center of spherical capsules
were used in the model, and the capsule thickness was varied from 50 to 350 μm. The
model assumes that the insulin-secreting β-cells act as sensors of both the local glucose
concentration and its change. Hence, a first-phase response related to the change in

























G3 G11 G3 KCl G3
Figure 2 Glucose-induced insulin secretion in unencapsulated (free) and encapsulated islets (blue
diamonds and red dots, respectively). Average of experimental data for free and alginate-encapsulated
mouse islets perifused in parallel using a low (3 mM; G3)→ high (11 mM; G11)→ low (G3) incoming glucose
stimulation (plus 5 min KCl followed by G3), as shown below the x-axis. Data represent the average ± SE for
three experiments performed in duplicate with ~ 50 IEQ per channel. Representative encapsulated islets used






























































Figure 3 Model-predicted effect of capsule thickness on GSIR perifusion. Calculated insulin outflow is
shown in response to a stepwise glucose stimulation with the current computational model for two encapsulated
islets (d = 100 & 150 μm) as a function of increasing capsule thickness (lcaps) from 0 (free islets) and 50 to 350 μm.
Shown on the right is an illustration of the main geometric setup used for the current model with fluid flow from
left to right, and 100 (top) and 150 (bottom) μm islets.
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Hill–type sigmoid response-functions of the local (i.e., cellular level) glucose concen-
tration, cgluc, and its time-gradient, ∂cgluc/∂t, resulting in second– and first–phase in-
sulin responses, respectively (Figure 1). Oxygen and glucose consumption by the islet
cells are incorporated in the model using Michaelis-Menten–type kinetics (i.e., Hill
equation with n = 1). Since lack of oxygen (hypoxia) can be an important limiting factor in
avascular islets [26], oxygen concentrations are also allowed to limit the rate of insulin se-
cretion, following again a Hill–type equation. Finally, all the local (cellular-level) oxygen,
glucose, and insulin concentrations are combined together with solute transfer equations
to calculate observable, external concentrations as a function of time and incoming
glucose and oxygen concentrations (see Computational methods and Additional file 1:
Appendix 1 for further details). Calculations were done using the same model parameter-
ized originally based on perifusion data from human islets [21], except the kinetics of in-
sulin release was increased slightly (kinsL = 0.006 s
−1 vs. the original 0.003 s−1) to account
for the somewhat sharper first phase response of murine islets observed here as compared
to human islets [34,43]. The effect of this change on the predicted insulin release profile
of free islets is shown in Figure 4. An important advantage of this model is that it allows
for calculation of the distribution of all concentrations of interest at any time-point during
the perifusion; an illustrative example of insulin concentration during the increase of in-
coming glucose concentration is shown in Figure 5 comparing the response of free and
encapsulated islets.
Obtained experimental insulin-release profiles could be fitted well with the present
model both for the free and encapsulated islets (r2 of 0.952 and 0.853, respectively)
(Figure 6). Remarkably, the total calculated outgoing flux, which requires scaling with
height data to convert the 2D flux to 3D values, gave the present fit shown in Figure 6
after scaling to 50 IEQ (i.e., an islet volume of 50 × 1.77·10−13 m3) – exactly the islet
equivalent (IEQ) number used in the experiments. This was particularly encouraging as












































free, k_insL = 0.006
free, k_insL = 0.003
G3 G11 G3
Figure 4 Effect on the insulin release profile of the single parameter adjustment used (kinsL = 0.006 s
−1
vs. the original 0.003 s−1) to fit release of murine islets with the model previously parameterized for
human islets (dark red vs. dashed purple lines, respectively).
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(Table 1), originally derived from human data, and indicates that they can give an ad-
equate description for murine islets as well (with the single adjustment of increasing
the kinsL value, see Figure 4).
Predicted responses for encapsulated islets depend on the thickness of the spherically
symmetric capsules assumed for the calculation (Figure 3). The fit shown in Figure 6 was
obtained with a capsule size of lcaps = 150 μm, which gave the lowest sum of squared er-
rors (SSE). Minimum SSE for the fitting was obtained with a capsule size of lcaps = 150 μm
and an IEQ of 50.6. While this thickness might be smaller than the average half-distance
for centrally located islets within these 800 μm diameter microbeads (see inset in Figure 2),Figure 5 Model-calculated insulin concentrations in response to increasing glucose concentrations.
Calculated insulin concentrations for two illustrative free and encapsulated islets (left and right, respectively;
d = 100 (top) & 150 μm (bottom), lcaps = 150 μm) under normoxic conditions. Data shown as surface plot
are insulin concentration (color-coded from blue for low to red for high. Streamlines show the flow of the
perifusion fluid (color-coded for velocity; flow from left to right) and colored contour lines show isolevels
for the perifusing glucose (from light blue for low to light red for high). Model calculated values are shown
during the increase of the glucose concentration from 3 mM to 11 mM; first phase response is noticeably

































Figure 6 Fit of the experimental glucose-induced insulin secretion in unencapsulated (free) and
encapsulated islets perifused in parallel with the computational model. Experimental data are the
same as in Figure 2; calculated insulin outflow in response to the same stepwise glucose is with the current
model for capsule thicknesses of 0 (free islets) and lcaps = 150 μm assuming islet sizes as shown in Figure 5 and
following a 2D to 3D conversion with a total islet volume scaled to 50 IEQ (see text).
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and that the most efficient exchange will take place along the shortest diffusional path to
the bead surface. Lacking corresponding experimental data, the effects of different algin-
ate concentrations were not modeled. However, they are expected to modify the diffusiv-
ities within the capsule and, ultimately, result in effects that are to a good extent similar
to those caused by changes in capsule thickness.
To allow acceptable computation times with adequate time-sampling along the entire
perifusion interval (~60 min), the present computational model is implemented as a 2D
model (Figure 3). However, we have shown previously that 2D models represent well
the results of the much more time consuming 3D models [21,26]. Another advantage
of the general nature of the present FEM model is that it allows easy expansion of the
model from simple passive diffusion within the capsule to incorporation of convective
flow of the aqueous media through the hydrogel capsule, which has been considered a
possibility in a few cases (e.g., [44,45]). This can be implemented by permitting flow,
but with increased viscosity, within the capsule. We did a brief exploration with such
an extended model on the impact of different viscosities for the flow within the encap-
sulating material on the overall pattern of flow and the predicted insulin profile (data
not shown), but we found them too similar to those of the diffusion-only model to
allow distinguishing between the models without further knowledge on the parameters
(i.e., viscosities vs. diffusion coefficients).
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eling of a free and an encapsulated islet side-by-side within the same chamber. Responses at
illustrative time-points (e.g., during the increase in glucose concentration) are shown in Fig-
ure 7, with corresponding animations included as Additional files 2 and 3. Of note, the
present experiments were performed at atmospheric oxygen (pO2 = 140 mmHg; coxy =
0.20 mM), while some other published perifusion experiments were performed using
oxygen-enriched perifusion media (e.g., 95% O2) to minimize the effects of oxygen limita-
tion. At lower oxygen concentrations, such as those mimicking the tissue oxygen con-
centrations that transplanted islets are likely to encounter (e.g., pO2 = 35–45 mmHg;
coxy = 0.05–0.065 mM), the loss in insulin secreting ability is likely to be more significant as
the encapsulated islets will be impacted more by hypoxia [21]. For example, our calculations
with this model under low oxygen conditions predicted that free islets can still secrete insulin
at around 70–75% of their normal rate, whereas encapsulated islets can only operate at
around 50% of the full rate, and their response is especially hampered at larger glucose levels.
To overcome this nutrient diffusion problem, many different approaches have been and are
being explored including, for example, use of smaller or more oxygen-permeable capsules,
co-encapsulation of anti-inflammatory drugs, use of smaller or more hypoxia-resistant islets,
local oxygen delivery near the islets, and others, as reviewed in detail elsewhere [10,12].Conclusions
Overall, the high-resolution experimental results collected herein are in agreement with
previous results [32,41,42,46], whereby the GSIR response of alginate microencapsulatedFigure 7 Model-predicted delay in insulin response and increased hypoxia for encapsulated islets shown
as three-dimensional surfaces. Side-by-side comparison of the GSIR response of free and encapsulated islets (both
having d= 150 μm; encapsulated islet on the right side) using a 3D surface representation of insulin (height data)
and oxygen (color code; blue = high; red = low). The corresponding 2D figure is included for reference (inset).
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what delayed and blunted – a difference that increases with increasing capsule thickness.
Optimization of encapsulation technologies to reduce the effects of diffusion limitations
(i.e., thinner capsules, smaller islets, increased diffusivities, incorporation of oxygen
delivery, or improved access to nearby blood-flow) could minimize the delay and
blunting of the first-phase response, which could be important as an accelerated loss
of the first-phase insulin response has been found in those progressing toward T1D
[47]. We found that these GSIR perifusion experiments could be very well modeled
by our local concentration-based FEM computational model, further confirming its
current parameterization. Because the model uses an unrestricted approach to couple
hormone secretion and nutrient consumption kinetics with diffusive and even convective
transport, it can be used for arbitrary geometries and glucose stimulation sequences.
Thus, it is well suited for the quantitative characterization of the insulin response of cul-
tured, perifused, transplanted, and encapsulated islets under various conditions.
Additional files
Additional file 1: Appendix 1. Local glucose and oxygen concentration-based finite element method (FEM) used
to model the insulin secretion of pancreatic islets (β-cells): Computational method details.
Additional file 2: Video A1: GlucInsDyn_wHalfEncaps_wParamGeo_Model20_v44_InsulinSurfaceHeight.avi.
Additional file 3: Animated GIF A2: GlucInsDyn_wHalfEncaps_wParamGeo_Model20_v44_InsConc01.gif.
Movie (.avi) and corresponding animated image (.gif) files showing the parallel comparison of the time-course of
the GSIR response of free and encapsulated islets (both having d = 150 μm; encapsulated islet on the right side) to
a glucose step (3 mM → 11 mM → 3 mM). The same 3D surface representation with insulin concentrations as
height data and oxygen concentration as color code (blue = high, red = low) is used as in Figure 7.
Abbreviations
FEM: Finite element method; GSIR: Glucose-stimulated insulin release; IEQ: Islet equivalent; SSE: Sum of squared errors;
T1D: Type 1 diabetes mellitus.
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